Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2014 / Article

Research Article | Open Access

Volume 2014 |Article ID 476430 | https://doi.org/10.1155/2014/476430

Mohamed A. Al-Kahtani, Ashraf M. Abdel-Moneim, Omar M. Elmenshawy, Mohamed A. El-Kersh, "Hemin Attenuates Cisplatin-Induced Acute Renal Injury in Male Rats", Oxidative Medicine and Cellular Longevity, vol. 2014, Article ID 476430, 9 pages, 2014. https://doi.org/10.1155/2014/476430

Hemin Attenuates Cisplatin-Induced Acute Renal Injury in Male Rats

Academic Editor: Madia Trujillo
Received11 May 2014
Revised30 Jul 2014
Accepted06 Sep 2014
Published22 Sep 2014


Background. The aim of this study is to investigate the protective effects of hemin (the heme oxygenase-1 [OH-1] inducer) against nephrotoxic effects induced by cisplatin [cis-diamminedichloroplatinum II (CP)] in male rats. Methods. The evaluation was performed through monitoring renal redox parameters: lipid peroxidation (LPO), glutathione peroxidase (GPx), superoxide dismutase (SOD), glutathione reductase (GR), and reduced glutathione (GSH). The work also examined renal function tests (urea and creatinine), tissue proinflammatory mediator like nitric oxide (NO), and kidney cytopathology. Results. A single intraperitoneal dose of CP (10 mg/kg b.w.) caused significant elevation of blood urea, serum creatinine, and renal LPO and NO, along with significant decline of the activities of GPx and GR, but renal SOD activity and GSH level were statistically insignificant as compared to control group. Subcutaneous injection of hemin (40 µmol/kg b.w.) partially ameliorated CP-induced renal damage, based on suppression of blood urea, serum creatinine, the renal MDA and NO levels, and increased antioxidant capacity in CP-treated rats. The results of histopathological and ultrastructural investigations supported the renoprotective effect of hemin against CP-induced acute toxicity. Conclusion. The induction of HO-1 by hemin is a promising approach in the treatment of CP-induced nephrotoxicity. However, further preclinical studies are warranted to test effectiveness of CP/hemin on the outcome of tumor chemotherapy.

1. Introduction

Cisplatin (cis-diamminedichloroplatinum(II), CP) is a highly effective chemotherapeutic agent against a large spectrum of tumor types [13]. However, the long-term clinical use of CP is limited by its serious side effects, mainly nephrotoxicity [4]. CP causes impairment of kidney function and acute renal failure via multiple mechanisms including generation of oxygen/nitrogen species, DNA damage, tubulointerstitial inflammation, and apoptotic cell death [512]. A number of studies have evaluated compounds as potential nephroprotectors against CP; these included natural antioxidants, modulators of nitric oxide synthesis, osmotic diuretics, and cytoprotective and antiapoptotic agents [13]. However, most of them were not found suitable/safe for clinical practice. In this context, heme oxygenase-1 (HO-1), the rate-limiting enzyme in heme catabolism, might offer a promising alternative. HO-1 (also known as heat shock protein 32) is induced by free radical-initiated reactions, and its induction is considered to be an adaptive response against oxidative tissue damage [1420]. In addition, HO-1 has been recognized to exhibit powerful anti-inflammatory and immunomodulatory effects [21]. Previous studies have shown that HO-1-inducing agents, as hemin, can mitigate nephrotoxic effects caused by a wide array of stressors, including mercury [15] and acetaminophen [20]. Based on the previous information, the present study aimed to examine whether the activation of HO-1 (by hemin) would have protective effects against CP induced nephrotoxicity in rats. For this purpose, we have evaluated the status of renal lipid peroxidative assay and antioxidant defenses. In addition, detailed glomerular and tubular pathologies were assessed.

2. Materials and Methods

2.1. Drugs and Chemicals

CP and hemin (powder) were purchased from Sigma Chemical Company, USA. Other chemical reagents were of high-quality analytical grade. Hemin was first dissolved in 0.1 M NaOH, titrated to pH 7.4 with 0.1 M HCl, and then diluted with normal saline (1 : 10 v/v), while CP was prepared in normal saline.

2.2. Animals and Treatments

Healthy adult male rats (110–140 g) were obtained from animal house facility at King Saud University, Saudi Arabia. Rats were housed in polyethylene cages under controlled laboratory conditions and provided with standard rat chow and water ad libitum. They were allowed 1 week of acclimatization before the initiation of the experiment. Experimental protocol of this study complies with the NIH ethical guidelines for the manipulation and care of laboratory animals. Rats were randomly assigned into 4 groups ():(i)saline group (control): rats received 3 mL/kg 0.09% NaCl, intraperitoneally (i.p.);(ii)CP group: rats received a single dose of CP, i.p. (10 mg/kg);(iii)CP+hemin group: rats received 40 μmol/kg hemin, subcutaneously (s.c.), 1 h following CP;(iv)hemin group: rats received 40 μmol/kg hemin, s.c.

Doses, duration, and routes of exposure were chosen according to previously published reports [20, 22]. All rats were sacrificed under light ether anesthesia after 24 h of the last dose of specific treatment, and samples of trunk blood and kidneys were collected. Blood was centrifuged at 5000 rpm for 10 min and the separated sera were used for measurement of renal function tests. Kidneys were decapsulated and washed in cold isotonic saline. The cortex was carefully separated from medulla as described earlier by Banday et al. [23]. The kidney cortex was homogenized (Glass Col homogenizer) and a 20% w/v homogenate was prepared in ice cold 50 mM, pH 7.4 phosphate buffer saline. The homogenate was centrifuged at 5000 rpm for 20 min and the supernatant was then saved in aliquots to avoid sample thawing and freezing and stored at −80°C till used for assaying peroxidative damage and antioxidant status. Samples of the intact kidney tissues were used for light and electron microscopic studies.

2.3. Markers of Renal Toxicity

Serum levels of urea and creatinine were measured spectrophotometrically using commercial diagnostic kits (Human Gesellschaft für Biochemica und Diagnostica mbH, Germany), according to the methods described by Tabacco et al. [24] and Bartels and Böhmer [25], respectively.

2.4. Oxidative Stress-Related Indices

Malondialdehyde (MDA), an index of fatty acid oxidation, was estimated in quantifiable amounts using Thiobarbituric Acid Reactive Substances (TBARS) assay kit (BioAssay Systems, CA, USA) according to the method of Ohkawa et al. [26]. In this procedure, MDA reacts with thiobarbituric acid (TBA) to form a pink-colored complex that has maximum absorbance at 532 nm. MDA value was calculated in terms of nmol/g wet tissue. Nitric oxide (NO) level was determined in kidney homogenates using Nitrate/Nitrite Colorimetric Assay Kit (BioAssay Systems, CA, USA) according to the manufacturer’s instructions. NO production was measured following reduction of nitrate to nitrite using improved Griess method [27]. Total NO synthetase (NOS) activity was detected by NOS assay kit (BioAssay Systems, CA, USA) [28]. Activities of glutathione peroxidase (GPx, EC and superoxide dismutase (SOD, EC as well as the level of reduced glutathione (GSH) in renal cortex were determined spectrophotometrically, according to the standard detection protocol of analysis kits (BioAssay Systems, CA, USA) [2931]. Glutathione reductase (GR, EC activity was assayed using a commercial kit from Cayman Chemical Company, USA [32]. Protein content was estimated by the method of Lowry et al. [33].

2.5. Light Microscopy

Kidney taken from each animal was fixed in 10% formalin solution, dehydrated in ascending series of ethanol, and embedded in paraffin. Sections (4 μm-thick) were cut, stained with haematoxylin and eosin solutions, and examined under light microscope (Nikon 80i, Japan).

2.6. Electron Microscopy

Small slices of kidney cortex ( per group) were fixed in 3% glutaraldehyde in sodium phosphate buffer (200 mM, pH 7.2) for 3 h at 4°C. Postfixation was in cold 1% osmium tetroxide (Agar Sci. Ltd., England) for 1 h. After flushing in phosphate buffer, the tissue samples were dehydrated in graded ethanol solutions and embedded in Araldite (Agar Sci. Ltd., England). Ultrathin sectioning (80–100 nm) was carried out using Leica EM UC6 (Leica Co., Austria) ultramicrotome. Sections were mounted on grids, double stained with 2% uranyl acetate and lead citrate, and viewed under Jeol JEM 1011 transmission electron microscope (Jeol Ltd., Japan) at 80 kV.

2.7. Statistics

All variables were compared using one-way analysis of variance (ANOVA) followed by LSD multiple range test. Differences at were considered significant. Statistical tests were performed using SAS statistical software (SAS v. 9.2, SAS Institute, Inc., Cary, NC). Data were presented as mean ± standard error (SE).

3. Results

3.1. Biochemical Findings

The results of biochemical analysis in all studied groups are shown in Table 1. Treatment of male rats with CP resulted in significant increases in levels of blood urea (3.1-fold) and creatinine (6.3-fold) compared to control animals, indicating renal damage. These changes were significantly reversed by hemin treatment. Hemin administration alone had no effect on kidney function. With respect to TBARS, renal levels were significantly higher in CP group than the control values, while TBARS levels were similar in CP plus hemin and control groups. The levels of NO in cortical tissue were significantly increased in rats injected with a single dose of CP as compared to control animals. Hemin treatment significantly decreased the elevated renal NO levels. In a similar manner, an elevation in NOS activity (4.6-fold) was observed in CP group compared to control group. In rats treated with hemin plus CP, the activity of NOS was decreased by 36.2% compared to CP-treated animals. On the other hand, the activities of GPx and GR were profoundly declined by approximately 30% in cortical homogenates of CP group compared to the corresponding control values. Administration of hemin prevented CP elicited decreases in activities of theses antioxidant enzymes. On the contrary, no statistically significant changes in SOD activity and GSH level were recorded after CP treatment; however, hemin administration either alone or in combination of CP enhanced renal GSH levels compared to the control group.

ParametersUnitControlCPCP + heminHemin

Ureamg/dL48.60 ± 1.50151.61 ± 10.02b86.61 ± 3.02b,c53.60 ± 3.20c
Creatininemg/dL0.81 ± 0.11 5.14 ± 0.76b 1.45 ± 0.69c0.78 ± 0.08c
TBARSnmole MDA/g tissue6.44 ± 1.67 11.00 ± 1.05b7.26 ± 2.74 4.06 ± 1.53c
NOmole/g tissue16.42 ± 0.9819.58 ± 1.50b13.16 ± 0.71b,c11.86 ± 0.84b,c
NOSnmole/g tissue5.56 ± 0.8425.61 ± 7.50b16.34 ± 2.196.07 ± 0.89c
GPxmU/mg protein353.51 ± 44.43238.49 ± 40.83b311.15 ± 25.76376.81 ± 30.18c
SODU/mg protein18.14 ± 2.7614.01 ± 1.8517.59 ± 1.8318.08 ± 1.15
GRmU/mg protein98.79 ± 8.4067.63 ± 6.03b86.26 ± 9.13105.75 ± 10.73c
GSHmole/mg protein6.68 ± 1.106.93 ± 0.599.15 ± 1.01b10.05 ± 0.37b,c

TBARS: thiobarbituric acid reactive substances, MDA: malondialdehyde, NO: nitric oxide, NOS: nitric oxide synthetase, GPx: glutathione peroxidase, SOD: superoxide dismutase, GR: Glutathione reductase, and GSH: reduced glutathione.
aResults are expressed as mean ± SE for six replicates.
bSignificantly different from control at < 0.05 by one-way ANOVA.
cSignificantly different from CP at < 0.05 by one-way ANOVA.
3.2. Kidney Histopathology

Representative light micrographs of renal cortex are illustrated in Figure 1. The histological picture of kidney was normal in both control (Figure 1(a)) and hemin-treated (Figure 1(e)) groups. In CP-treated rats (Figures 1(b)-1(c)), the renal corpuscles displayed extensive congestion filling up the glomerular capillary loops. Some glomeruli were atrophied or lost with concurrent dilatation of Bowman’s space. The morphological deterioration was also characterized by a widespread tubular cell swelling, necrosis, and degeneration, occurring primarily in proximal convoluted tubules (PCTs) epithelia. In addition, peritubular inflammatory cell infiltrations and hemorrhagic foci were clearly apparent after CP treatment. In contrast, these histological abnormalities were found to be reduced in CP plus hemin-treated rats (Figure 1(d)). Table 2 shows a semiquantitative analysis of renal lesions in rats treated with CP with or without hemin.

GroupControlCPCP + heminHemin

Glomerular congestion+++
Glomerular atrophy+++
Peritubular inflammatory cell infiltration++++
Tubular damage++++

Scoring scale: none (—), mild (+), moderate (++), and severe (+++).
3.3. Electron Microscopic Observations

Renal cortical tissues of control animals revealed normal appearance of ultrastructural patterns of renal corpuscles and tubules (Figures 2(a)2(c)). Obvious ultrastructural changes were noted in the glomeruli of CP-treated rats (Figure 3(a)). We observed progressive deformation of capillary endothelial cells, including hypertrophy (i.e., swelling), hyperplasia, and focal loss of fenestrae. The secondary foot processes of podocytes were deteriorated and markedly fused in some places. The Glomerular Basement Membrane (GBM) was corrugated and displayed uneven thickening. The mesangium was expanded with massive increase in matrix. Examination of PCTs of CP group revealed the presence of destructed/irregular microvilli, apical vacuoles, large secondary lysosomes, altered mitochondria, and accumulation of myeloid bodies in the cytoplasm (Figure 3(b)). The distal convoluted tubules (DCTs) epithelia of CP-treated rats lost most of their cytoplasmic electron density and cellular organelles (Figure 3(c)). Apoptotic cells were also seen and identified by cell shrinkage, degradation of chromatin, and membrane blebs. CP plus hemin group showed marked recovery in the ultrastructural aspect of glomeruli and cellular features of renal tubules (Figures 4(a)4(c)).

4. Discussion

Kidneys are dynamic organs and represent one of the major homeostasis body systems; they are affected by diverse varieties of chemicals and drugs [3436]. Platinum complexes (such as CP) are highly nephrotoxic, which predominantly accumulate in the kidneys [37]. It is evident from the present study that administration of a single dose of CP (7.5 mg/kg i.p.) resulted in acute tubule cell necrosis, interstitial inflammation, and glomerular congestion and atrophy. Besides, renal function biochemical parameters such as blood urea and creatinine were markedly elevated in CP-treated rats compared to control group, reflecting early damage of the filtration barrier (i.e., the fenestrated capillary endothelium, GBM, and visceral epithelial podocytes). These results are in agreement with previous reports in murine models [37, 38]. Hemin significantly suppressed the increases in blood urea and serum creatinine, which may be due to improvement in glomerular filtration damage induced by CP.

Development of therapies to prevent free radicals generation may influence renal oxidative damage and protect against irreversible cell damage and necrosis induced by CP. Excessive ROS production by CP causes antioxidant imbalance and leads to progressive LPO and antioxidant depletion. LPO adducts were previously shown to mediate glomerular lesions [39]. In addition, peroxidation of membrane phospholipids increases membrane fluidity and permeability and results in hypertrophy (i.e., swelling) of renal tubule cells and degeneration of cell organelles, such as nuclei and mitochondria [40]. ROS production is further stimulated by damaged mitochondria in CP nephrotoxicity [8]. Our results showed that CP induced a significant elevation in MDA (a secondary product of LPO) and decrease in activities of GPx and GR, which are in agreement with previous studies [11, 4144]. In line with these data, the formation of large myeloid bodies (i.e., multilamellated lysosomes), as observed in PCTs epithelia of CP group, has been a hallmark alteration indicative of an inhibited or altered function of intracytoplasmic enzymatic machinery [45]. The administration of hemin decreased or abolished kidney oxidative stress/LPO and increased antioxidant potentials. Hemin was reported to induce HO-1 protein which exerts cellular protection against renal toxicants [15]. HO-1 expression blocks injury pathways by catalyzing the breakdown of prooxidant heme into biliverdin (BV), carbon monoxide (CO), and ferrous iron (Fe+2)/ferritin. BV formed in this reaction is rapidly recycled by the action of biliverdin reductase into bilirubin (BR) which has a higher free radical-scavenging activity and antiapoptotic properties [4649]. In addition, CO triggers the nuclear factor-erythroid 2-related factor 2 (Nrf2) to increase the expression and function of a battery of antioxidant enzymes [50]. Kim et al. [51] demonstrated that hemin substantially stimulates nuclear translocation of Nrf2 and its subsequent binding to antioxidant responsive element (ARE), a regulatory enhancer sequence in the promoter region of the involved genes.

Treatment with CP overdose induces nitrosative stress by NO and other nitrosylating agents and this was correlated with the expression of the inducible nitric oxide synthase (iNOS) protein [52]. In the current study, NO production in the CP-treated group was significantly higher than that in the control group; our results are consistent with the results obtained by Kart et al. [53], who have shown that there is strong immunoreactivity against iNOS in the liver tissue of the CP-treated group. Recent work of Chirino et al. [54] reported that the downregulation of iNOS expression reduced CP-induced renal damage and nitrosative stress. High NO levels exert toxicological effects by reacting with superoxide anion to generate short-lived but hyperactive peroxynitrite radical with subsequent nitration of protein tyrosine residues [55, 56]. Also, NO output depletes intracellular GSH, which increases susceptibility to oxidative stress and aggravates renal tissue damage [57, 58], especially for glomerular diseases (e.g., lupus nephritis) [59]. Hemin-mediated augmentation of HO-1 activity was proved to be efficient enough to reduce the NO-dependent pathological and inflammatory conditions [17, 60, 61]. Of note, HO-1 and its reaction product CO also suppress the expression of iNOS protein by preventing the activation of nuclear factor-kappa B (NF-κB) which upregulates the transcription of the iNOS gene [17, 62, 63].

In conclusion, this study is the first to demonstrate the protective role of hemin (an HO-1 activator) against acute nephrotoxicity induced by CP. Treatment of hemin ameliorated renal ultrastructural changes and dysfunction, and this was associated with reduction of LPO, overstimulation of antioxidant capacity, and suppression of NO biosynthesis, the proinflammatory mediator. However, further preclinical studies are needed to verify whether coadministration of CP and hemin could affect the outcome of tumor chemotherapy.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.


The authors thank the Deanship of Scientific Research, King Faisal University, for financial and moral support of this work (Project no. 130142).


  1. S. Atasayar, H. Gürer-Orhan, H. Orhan, B. Gürel, G. Girgin, and H. Özgüneş, “Preventive effect of aminoguanidine compared to vitamin E and C on cisplatin-induced nephrotoxicity in rats,” Experimental and Toxicologic Pathology, vol. 61, no. 1, pp. 23–32, 2009. View at: Publisher Site | Google Scholar
  2. I. Hassan, S. Chibber, and I. Naseem, “Ameliorative effect of riboflavin on the cisplatin induced nephrotoxicity and hepatotoxicity under photoillumination,” Food and Chemical Toxicology, vol. 48, no. 8-9, pp. 2052–2058, 2010. View at: Publisher Site | Google Scholar
  3. A. Naqshbandi, M. W. Khan, S. Rizwan, S. U. Rehman, and F. Khan, “Studies on the protective effect of dietary fish oil on cisplatin induced nephrotoxicity in rats,” Food and Chemical Toxicology, vol. 50, no. 2, pp. 265–273, 2012. View at: Publisher Site | Google Scholar
  4. M. A. C. Rodrigues, J. L. Rodrigues, N. M. Martins et al., “Carvedilol protects against cisplatin-induced oxidative stress, redox state unbalance and apoptosis in rat kidney mitochondria,” Chemico-Biological Interactions, vol. 189, no. 1-2, pp. 45–51, 2011. View at: Publisher Site | Google Scholar
  5. L. M. G. Antunes, J. D. C. Darin, and M. de Lourdes P. Bianchi, “Protective effects of vitamin C against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats: a dose-dependent study,” Pharmacological Research, vol. 41, no. 4, pp. 405–411, 2000. View at: Publisher Site | Google Scholar
  6. O. A. Badary, S. Abdel-Maksoud, W. A. Ahmed, and G. H. Owieda, “Naringenin attenuates cisplatin nephrotoxicity in rats,” Life Sciences, vol. 76, no. 18, pp. 2125–2135, 2005. View at: Publisher Site | Google Scholar
  7. H. D. C. Francescato, R. S. Costa, C. Scavone, and T. M. Coimbra, “Parthenolide reduces cisplatin-induced renal damage,” Toxicology, vol. 230, no. 1, pp. 64–75, 2007. View at: Publisher Site | Google Scholar
  8. X. Yao, K. Panichpisal, N. Kurtzman, and K. Nugent, “Cisplatin nephrotoxicity: a review,” The American Journal of the Medical Sciences, vol. 334, no. 2, pp. 115–124, 2007. View at: Publisher Site | Google Scholar
  9. Y. I. Chirino, D. J. Sánchez-González, C. M. Martínez-Martínez, C. Cruz, and J. Pedraza-Chaverri, “Protective effects of apocynin against cisplatin-induced oxidative stress and nephrotoxicity,” Toxicology, vol. 245, no. 1-2, pp. 18–23, 2008. View at: Publisher Site | Google Scholar
  10. J. M. Pérez-Rojas, C. E. Guerrero-Beltrán, C. Cruz, D. J. Sánchez-González, C. M. Martínez-Martínez, and J. Pedraza-Chaverri, “Preventive effect of tert-butylhydroquinone on cisplatin-induced nephrotoxicity in rats,” Food and Chemical Toxicology, vol. 49, no. 10, pp. 2631–2637, 2011. View at: Publisher Site | Google Scholar
  11. R. Domitrović, O. Cvijanović, E. Pernjak-Pugel, M. Škoda, L. Mikelić, and Ž. Crnčević-Orlić, “Berberine exerts nephroprotective effect against cisplatin-induced kidney damage through inhibition of oxidative/nitrosative stress, inflammation, autophagy and apoptosis,” Food and Chemical Toxicology, vol. 62, pp. 397–406, 2013. View at: Publisher Site | Google Scholar
  12. H. Pan, K. Shen, X. Wang, H. Meng, C. Wang, and B. Jin, “Protective effect of metalloporphyrins against Cisplatin-induced kidney injury in mice,” PLoS ONE, vol. 9, no. 1, Article ID e86057, 2014. View at: Publisher Site | Google Scholar
  13. B. H. Ali and M. S. Al Moundhri, “Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research,” Food and Chemical Toxicology, vol. 44, no. 8, pp. 1173–1183, 2006. View at: Publisher Site | Google Scholar
  14. H. P. Kim, H.-O. Pae, S. H. Back et al., “Heme oxygenase-1 comes back to endoplasmic reticulum,” Biochemical and Biophysical Research Communications, vol. 404, no. 1, pp. 1–5, 2011. View at: Publisher Site | Google Scholar
  15. R. Yoneya, H. Ozasa, Y. Nagashima et al., “Hemin pretreatment ameliorates aspects of the nephropathy induced by mercuric chloride in the rat,” Toxicology Letters, vol. 116, no. 3, pp. 223–229, 2000. View at: Publisher Site | Google Scholar
  16. H. Chiu, J. A. Brittingham, and D. L. Laskin, “Differential induction of heme oxygenase-1 in macrophages and hepatocytes during acetaminophen-induced hepatotoxicity in the rat: effects of hemin and biliverdin,” Toxicology and Applied Pharmacology, vol. 181, no. 2, pp. 106–115, 2002. View at: Publisher Site | Google Scholar
  17. T. Wen, Z.-M. Wu, Y. Liu, Y.-F. Tan, F. Ren, and H. Wu, “Upregulation of heme oxygenase-1 with hemin prevents d-galactosamine and lipopolysaccharide-induced acute hepatic injury in rats,” Toxicology, vol. 237, no. 1–3, pp. 184–193, 2007. View at: Publisher Site | Google Scholar
  18. Y.-S. Chen, X.-X. Zhu, X.-Y. Zhao, H.-Y. Xing, and Y.-G. Li, “Hemin, a heme oxygenase-1 inducer, improves aortic endothelial dysfunction in insulin resistant rats,” Chinese Medical Journal, vol. 121, no. 3, pp. 241–247, 2008. View at: Google Scholar
  19. A. A. Fouad, H. A. Qureshi, A. I. Al-Sultan, M. T. Yacoubi, and A. A. Ali, “Protective effect of hemin against cadmium-induced testicular damage in rats,” Toxicology, vol. 257, no. 3, pp. 153–160, 2009. View at: Publisher Site | Google Scholar
  20. A. A. Fouad, M. T. Yacoubi, and M. H. El-Bidawy, “Therapeutic potential of hemin in acetaminophen nephrotoxicity in rats,” Environmental Toxicology and Pharmacology, vol. 27, no. 2, pp. 277–282, 2009. View at: Publisher Site | Google Scholar
  21. C. S. T. Origassa and N. O. S. Câmara, “Cytoprotective role of heme oxygenase-1 and heme degradation derived end products in liver injury,” World Journal of Hepatology, vol. 5, no. 10, pp. 541–549, 2013. View at: Publisher Site | Google Scholar
  22. A. Hussein, A. A. E. Ahmed, S. A. Shouman, and S. Sharawy, “Ameliorating effect of DL-α-lipoic acid against cisplatin-induced nephrotoxicity and cardiotoxicity in experimental animals,” Drug Discoveries & Therapeutics, vol. 6, no. 3, pp. 147–156, 2012. View at: Google Scholar
  23. A. A. Banday, N. Farooq, S. Priyamvada, A. N. K. Yusufi, and F. Khan, “Time dependent effects of gentamicin on the enzymes of carbohydrate metabolism, brush border membrane and oxidative stress in rat kidney tissues,” Life Sciences, vol. 82, no. 9-10, pp. 450–459, 2008. View at: Publisher Site | Google Scholar
  24. A. Tabacco, F. Meiattini, E. Moda, and P. Tarli, “Simplified enzymic/colorimetric serum urea nitrogen determination,” Clinical Chemistry, vol. 25, no. 2, pp. 336–337, 1979. View at: Google Scholar
  25. H. Bartels and M. Böhmer, “Micro-determination of Creatinine,” Clinica Chimica Acta, vol. 32, no. 1, pp. 81–85, 1971. View at: Publisher Site | Google Scholar
  26. H. Ohkawa, N. Ohishi, and K. Yagi, “Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction,” Analytical Biochemistry, vol. 95, no. 2, pp. 351–358, 1979. View at: Publisher Site | Google Scholar
  27. P. Bulau, D. Zakrzewicz, K. Kitowska et al., “Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 292, no. 1, pp. L18–L24, 2007. View at: Publisher Site | Google Scholar
  28. D. Ghigo, C. Riganti, E. Gazzano, C. Costamagna, and A. Bosia, “Cycling of NADPH by glucose 6-phosphate dehydrogenase optimizes the spectrophotometric assay of nitric oxide synthase activity in cell lysates,” Nitric Oxide—Biology and Chemistry, vol. 15, no. 2, pp. 148–153, 2006. View at: Publisher Site | Google Scholar
  29. B. Jacobson, G. Quigley, and G. Lockitch, “Adaptation of glutathione peroxidase assay to the Technicon RA-1000,” Clinical Chemistry, vol. 34, no. 10, pp. 2164–2165, 1988. View at: Google Scholar
  30. H. Ukeda, S. Maeda, T. Ishii, and M. Sawamura, “Spectrophotometric assay for superoxide dismutase based on tetrazolium salt 3'-{1-[(phenylamino)-carbonyl]-3,4-tetrazolium}-bis(4-methoxy-6- nitro)benzenesulfonic acid hydrate reduction by xanthine-xanthine oxidase,” Analytical Biochemistry, vol. 251, no. 2, pp. 206–209, 1997. View at: Publisher Site | Google Scholar
  31. I. Carlberg and B. Mannervik, “Glutathione reductase,” Methods in Enzymology, vol. 113, pp. 484–490, 1985. View at: Publisher Site | Google Scholar
  32. H. Lindenmaier, M. Becker, W. E. Haefeli, and J. Weiss, “Interaction of progestins with the human multidrug resistance-associated protein 2 (MRP2),” Drug Metabolism and Disposition, vol. 33, no. 11, pp. 1576–1579, 2005. View at: Publisher Site | Google Scholar
  33. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, “Protein measurement with the Folin phenol reagent,” The Journal of biological chemistry, vol. 193, no. 1, pp. 265–275, 1951. View at: Google Scholar
  34. A. M. Abdel-Moneim and K. M. Said, “Acute effect of cadmium treatment on the kidney of rats: biochemical and ultrastructural studies,” Pakistan Journal of Biological Sciences, vol. 10, no. 20, pp. 3497–3506, 2007. View at: Publisher Site | Google Scholar
  35. M. A. Al Kahtani, A. M. Abdel-Moneim, and W. M. El-Sayed, “The influence of taurine pretreatment on aluminum chloride induced nephrotoxicity in Swiss albino mice,” Histology and Histopathology, vol. 29, no. 1, pp. 45–55, 2014. View at: Google Scholar
  36. N. A. Salem and E. A. Salem, “Renoprotective effect of grape seed extract against oxidative stress induced by gentamicin and hypercholesterolemia in rats,” Renal Failure, vol. 33, no. 8, pp. 824–832, 2011. View at: Publisher Site | Google Scholar
  37. N. E. Abdelmegmd, H. N. Chmaisseand, and N. S. Abou Zeinab, “Silymarin ameliorates Cisplatin-induced hepatotoxicity in rats: histopathological and ultrastructural studies,” Pakistan Journal of Biological Sciences, vol. 13, no. 10, pp. 463–479, 2010. View at: Publisher Site | Google Scholar
  38. M. Morigi, B. Imberti, C. Zoja et al., “Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure,” Journal of the American Society of Nephrology, vol. 15, no. 7, pp. 1794–1804, 2004. View at: Publisher Site | Google Scholar
  39. C. J. Binder, H. Weiher, M. Exner, and D. Kerjaschki, “Glomerular overproduction of oxygen radicals in Mpv17 gene-inactivated mice causes podocyte foot process flattening and proteinuria. A model of steroid-resistant nephrosis sensitive to radical scavenger therapy,” The American Journal of Pathology, vol. 154, no. 4, pp. 1067–1075, 1999. View at: Publisher Site | Google Scholar
  40. E. C. Foulkes, Biological Membranes in Toxicology, Taylor and Francis, Philadelphia, Pa, USA, 1988.
  41. K. Sueishi, K. Mishima, K. Makino et al., “Protection by a radical scavenger edaravone against cisplatin-induced nephrotoxicity in rats,” European Journal of Pharmacology, vol. 451, no. 2, pp. 203–208, 2002. View at: Publisher Site | Google Scholar
  42. S. Işeri, F. Ercan, N. Gedik, M. Yüksel, and I. Alican, “Simvastatin attenuates cisplatin-induced kidney and liver damage in rats,” Toxicology, vol. 230, no. 2-3, pp. 256–264, 2007. View at: Publisher Site | Google Scholar
  43. M. Ekor, G. O. Emerole, and E. O. Farombi, “Phenolic extract of soybean (Glycine max) attenuates cisplatin-induced nephrotoxicity in rats,” Food and Chemical Toxicology, vol. 48, no. 4, pp. 1005–1012, 2010. View at: Publisher Site | Google Scholar
  44. Y.-N. Li, Y. Guo, M.-M. Xi et al., “Saponins from Aralia taibaiensis attenuate D-galactose-induced aging in rats by activating FOXO3a and Nrf2 pathways,” Oxidative Medicine and Cellular Longevity, vol. 2014, Article ID 320513, 13 pages, 2014. View at: Publisher Site | Google Scholar
  45. A. Hermenean, A. Ardelean, M. Stan et al., “Protective effects of naringenin on carbon tetrachloride-induced acute nephrotoxicity in mouse kidney,” Chemico-Biological Interactions, vol. 205, no. 2, pp. 138–147, 2013. View at: Publisher Site | Google Scholar
  46. D. E. Barañano, M. Rao, C. D. Ferris, and S. H. Snyder, “Biliverdin reductase: a major physiologic cytoprotectant,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 25, pp. 16093–16098, 2002. View at: Publisher Site | Google Scholar
  47. N. G. Abraham, J. Cao, D. Sacerdoti, X. Li, and G. Drummond, “Heme oxygenase: the key to renal function regulation,” American Journal of Physiology: Renal Physiology, vol. 297, no. 5, pp. F1137–F1152, 2009. View at: Publisher Site | Google Scholar
  48. S. W. Ryter and A. M. Choi, “Heme oxygenase-1/carbon monoxide: novel therapeutic strategies in critical care medicine,” Current Drug Targets, vol. 11, no. 12, pp. 1485–1494, 2010. View at: Publisher Site | Google Scholar
  49. Y. Naito, T. Takagi, K. Uchiyama, and T. Yoshikawa, “Heme oxygenase-1: a novel therapeutic target for gastrointestinal diseases,” Journal of Clinical Biochemistry and Nutrition, vol. 48, no. 2, pp. 126–133, 2011. View at: Publisher Site | Google Scholar
  50. K. Chan, X.-D. Han, and Y. W. Kan, “An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 8, pp. 4611–4616, 2001. View at: Publisher Site | Google Scholar
  51. Y.-C. Kim, H. Masutani, Y. Yamaguchi, K. Itoh, M. Yamamoto, and J. Yodoi, “Hemin-induced activation of the thioredoxin gene by Nrf2: a differential regulation of the antioxidant responsive element by a switch of its binding factors,” The Journal of Biological Chemistry, vol. 276, no. 21, pp. 18399–18406, 2001. View at: Publisher Site | Google Scholar
  52. R. D. Curran, F. K. Ferrari, P. H. Kispert et al., “Nitric oxide and nitric oxide-generating compounds inhibit hepatocyte protein synthesis,” The FASEB Journal, vol. 5, no. 7, pp. 2085–2092, 1991. View at: Google Scholar
  53. A. Kart, Y. Cigremis, M. Karaman, and H. Ozen, “Caffeic acid phenethyl ester (CAPE) ameliorates cisplatin-induced hepatotoxicity in rabbit,” Experimental and Toxicologic Pathology, vol. 62, no. 1, pp. 45–52, 2010. View at: Publisher Site | Google Scholar
  54. Y. I. Chirino, J. Trujillo, D. J. Sánchez-González et al., “Selective iNOS inhibition reduces renal damage induced by cisplatin,” Toxicology Letters, vol. 176, no. 1, pp. 48–57, 2008. View at: Publisher Site | Google Scholar
  55. R. Radi, G. Peluffo, M. N. Alvarez, M. Naviliat, and A. Cayota, “Unraveling peroxynitrite formation in biological systems,” Free Radical Biology and Medicine, vol. 30, no. 5, pp. 463–488, 2001. View at: Publisher Site | Google Scholar
  56. P. Pacher, J. S. Beckman, and L. Liaudet, “Nitric oxide and peroxynitrite in health and disease,” Physiological Reviews, vol. 87, no. 1, pp. 315–424, 2007. View at: Publisher Site | Google Scholar
  57. R. M. Clancy and S. B. Abramson, “Nitric oxide: a novel mediator of inflammation,” Proceedings of the Society for Experimental Biology and Medicine, vol. 210, no. 2, pp. 93–101, 1995. View at: Publisher Site | Google Scholar
  58. P. Liu, C. E. Hock, R. Nagele, and P. Y. Wong, “Formation of nitric oxide, superoxide, and peroxynitrite in myocardial ischemia-reperfusion injury in rats,” The American Journal of Physiology, vol. 272, no. 5, part 2, pp. H2327–H2336, 1997. View at: Google Scholar
  59. Y. Takeda, M. Takeno, M. Iwasaki et al., “Chemical induction of HO-1 suppresses lupus nephritis by reducing local iNOS expression and synthesis of anti-dsDNA antibody,” Clinical and Experimental Immunology, vol. 138, no. 2, pp. 237–244, 2004. View at: Publisher Site | Google Scholar
  60. B.-M. Choi, H.-O. Pae, Y.-M. Kim, and H.-T. Chung, “Nitric oxide-mediated cytoprotection of hepatocytes from glucose deprivation-induced cytotoxicity: involvement of heme oxygenase-1,” Hepatology, vol. 37, no. 4, pp. 810–823, 2003. View at: Publisher Site | Google Scholar
  61. S. Yang, H.-J. Shih, Y.-C. Chow et al., “The protective role of heme oxygenase-1 induction on testicular tissues after testicular torsion and detorsion,” The Journal of Urology, vol. 177, no. 5, pp. 1928–1933, 2007. View at: Publisher Site | Google Scholar
  62. T. Ashino, R. Yamanaka, M. Yamamoto et al., “Negative feedback regulation of lipopolysaccharide-induced inducible nitric oxide synthase gene expression by heme oxygenase-1 induction in macrophages,” Molecular Immunology, vol. 45, no. 7, pp. 2106–2115, 2008. View at: Publisher Site | Google Scholar
  63. A. Taye and B. M. Ibrahim, “Activation of renal haeme oxygenase-1 alleviates gentamicin-induced acute nephrotoxicity in rats,” Journal of Pharmacy and Pharmacology, vol. 65, no. 7, pp. 995–1004, 2013. View at: Publisher Site | Google Scholar

Copyright © 2014 Mohamed A. Al-Kahtani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.